Improving patient health outcomes and quality of life

Driving innovation through strategic partnerships

Advancing patient care with next-generation dendrimer technology

Starpharma Holdings Limited (ASX: SPL, OTCQX: SPHRY) is dedicated to helping patients with significant illnesses, such as cancer, achieve improved health outcomes and quality of life through the application of our unique dendrimer technology. 

Dendrimers are precise, synthetically manufactured nanoscale molecules that offer a range of benefits in pharmaceutical applications. Their unique properties, such as size, structure, high degree of branching, polyvalency, and water solubility, make them a valuable tool in our mission to improve health outcomes. 

Starpharma utilises its dendrimer technology to develop novel therapeutics and enhance the performance of existing pharmaceuticals. 

“Starpharma's dendrimer technology can make a real and important contribution to the fight against a range of diseases. Through our robust partnerships with global industry leaders, we are uniquely positioned to address these challenges."

Mr Robert Thomas AO

Starpharma Chairman


What are dendrimers?

What are dendrimers?

Dendrimers are precisely manufactured nanoparticles with unique properties, such as size, structure, branching, polyvalency, and water solubility, making them advantageous in medical and pharmaceutical applications.

How does DEP® work?

How does DEP® work?

Starpharma has developed the DEP® (dendrimer enhanced product) drug delivery platform to enhance the delivery and effectiveness of pharmaceutical drugs. This technology has the potential to offer significant therapeutic and commercial opportunities for a wide range of drugs across various therapeutic areas.

Our DEP® pipeline

Our DEP® pipeline

Starpharma has developed a pipeline of novel DEP® oncology products. Its clinical-stage assets, DEP® irinotecan, DEP® cabazitaxel, and DEP® docetaxel, are dendrimer versions of widely used chemotherapeutic drugs that have demonstrated improvements in efficacy and tolerability in Phase 2 clinical trials. Additionally, Starpharma has a preclinical pipeline of DEP® radiopharmaceuticals and DEP® Antibody-Drug Conjugates (ADCs) in development.

Partner with Starpharma

Partner with Starpharma

Commercial partnerships are key to Starpharma's business and offer significant optionality. Our partnerships involve leveraging our proprietary dendrimer technology platform to develop and commercialise innovative products to meet significant clinical needs and create value for all stakeholders.

Products in the market

Products in the market

Starpharma has developed and commercialised three products based on its innovative proprietary dendrimer called SPL7013 (astodrimer sodium), which has antiviral and antimicrobial properties through a physical mechanism of action. These products are marketed in regions where marketing authorisation has been achieved.

Information for Investors

Information for Investors

Starpharma is listed on the Australian Securities Exchange (ASX: SPL) and the US OTCQX (OTCQX: SPHRY). Our Investor Centre contains Starpharma's financial reports and presentations, corporate governance policy, and other information for investors.

This website is intended for people seeking information about Starpharma for investment and business purposes. This website contains information about products that may not be available, or approved, in all countries, or may be available under different trademarks, or for different indications. Individuals seeking information about a Starpharma product should visit the relevant product website in their country of residence or consult a healthcare provider. Nothing contained on this site should be considered a solicitation, promotion, or advertisement for any product, including those under development. Any information on this site is not intended to provide medical advice nor should be used as a substitute for the advice provided by a doctor or other healthcare provider.